Light and Sound Therapy Did Not Slow Alzheimer's Decline in a Yearlong Trial

Cognito's Spectris, a headset that aims to treat Alzheimer's disease with flickering light and rhythmic sound, failed the main test of a 673-participant trial, the company announced Nov. 16, 2026. The company said that in the full group of patients with mild-to-moderate Alzheimer's disease, a year of daily use left them no better off than a sham device, and that the trial's secondary measures showed no significant differences either.
The device pairs goggles with headphones and is worn for an hour a day at home. Cognito says the light and sound are timed to drive brain activity at 40 Hz, a rhythm it links to attention, perception and memory.
The company's own release leads on a different result. Among the 395 participants who entered with milder disease, a subgroup defined in advance, Cognito reported 56% slowing of decline on a measure of daily function and 47% on a measure of cognition and function. It marks both figures as nominal, meaning they are not corrected for the number of measures tested. Chief Executive Christian Howell said in the release, "We had hoped to see an effect across that overall population, and we did not." Cognito intends to seek FDA authorization for use in early symptomatic Alzheimer's disease.
Nature's news desk covered the conference presentation independently and reported that active-device users in the mild group declined 41.6% more slowly over the year than sham users.
"The trial was negative," Eric McDade, a neurologist at Washington University School of Medicine in St. Louis who was not involved in the study, told Nature. For Rob Howard, a psychiatrist at University College London who specializes in dementia, the subgroup data is exploratory rather than persuasive proof of effect. "If this was a drug, such a clear failure would mean that a company would not proceed to seek regulatory approval," Howard said. He noted that earlier trials have not succeeded either; a smaller study of the device failed in 2024.
Cognito reported no unanticipated adverse device effects in either arm. Spectris AD has not been authorized by the FDA, and the release states that its safety and effectiveness have not been established.
